Zentiva, a Czechia-based generics pharmaceutical company, announced on Friday that it has received the ESG Transparency Award 2025, presented by German market research organisation EUPD Group at the ESG Summit 2025.
The award aims to recognise companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.
EUPD Group said that Zentiva was awarded the Excellence Level of the ESG Transparency Award for its high degree of clarity, accessibility and transparency in sustainability reporting. This distinction places the company among the top organisations in Europe in terms of transparent reporting of its ESG disclosures.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules